Hospitals and adult treatments – we need your help

In a recent update we mentioned that hospitals were going to be asked to submit expressions of interest to provide Spinraza for adult patients. We can now confirm that that request has gone out and it is now down to hospitals to submit to NHS England.

We, as a community, really need to push hospitals into submitting their expression of interest. We are already hearing some large and well-known hospitals around the country are refusing to submit and therefore will not be providing access to adults.

The problem we have is that there are limited hospitals with skills to be able to provide the service. If some of those decide not to provide it then we could have huge swathes of the country without access locally. This means patients will need to be referred to other centres potentially long distances from home. Will also put pressure on the smaller number of centres who did provide a solution, meaning longer waiting lists and further delays for treatment.

We would urge all of you to contact your local hospital and ask them if they submitting an expression of interest for providing Spinraza to adults, and if not, why not? This needs to be locally driven in each area but we are happy to support. Please let us know what the responses are and also if you need any assistance. The fight is not over yet, we have contacts in media and MPs who we can approach.

TreatSMA team

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more